Abstract

Lentiviral vectors (LVs) are robust delivery vehicles for gene therapy as they can efficiently integrate transgenes into host cell genomes. However, LVs with lengthy or complex expression cassettes typically are produced at low titers and have reduced gene transfer capacity, creating barriers for clinical and commercial applications. Modifications of the packaging cell line and methods may be able to produce complex vectors at higher titer and infectivity and may improve production of many different LVs. In this study, we identified two host restriction factors in HEK293T packaging cells that impeded LV production, 2'-5'-oligoadenylate synthetase 1 (OAS1) and low-density lipoprotein receptor (LDLR). Knocking out these two genes separately led to ∼2-fold increases in viral titer. We created a monoclonal cell line, CRISPRed HEK293T to Disrupt Antiviral Response (CHEDAR), by successively knocking out OAS1, LDLR, and PKR, a previously identified factor impeding LV titers. Packaging in CHEDAR yielded ∼7-fold increases in physical particles, full-length vector RNA, and vector titers. In addition, overexpressing transcription elongation factors, SPT4 and SPT5, during packaging improved the production of full-length vector RNA, thereby increasing titers by ∼2-fold. Packaging in CHEDAR with over-expression of SPT4 and SPT5 led to ∼11-fold increases of titers. These approaches improved the production of a variety of LVs, especially vectors with low titers or with internal promoters in the reverse orientation, and may be beneficial for multiple gene therapy applications.

Highlights

  • Transplantation of autologous hematopoietic stem cells modified by lentiviral-based gene therapy has successfully treated multiple genetic blood cell diseases.[1,2,3,4] Lentiviral vectors (LVs) allow integration of transgenes into the host cell genomes of both dividing and nondividing cells, providing long-term stable expression of the gene of interest

  • We showed that knocking out protein kinase R (PKR), oligoadenylate synthetase 1 (OAS1), and low-density lipoprotein receptor (LDLR) additively increased the titer of various LVs by $7-fold, complex and lengthy LVs with low titers

  • PKRÀ/À cells were used as a positive control for the packaging process because we previously showed that knocking out PKR increased the titers of reverse-oriented LVs, such as Lenti/bAS3-FB.[24]

Read more

Summary

Introduction

Transplantation of autologous hematopoietic stem cells modified by lentiviral-based gene therapy has successfully treated multiple genetic blood cell diseases.[1,2,3,4] Lentiviral vectors (LVs) allow integration of transgenes into the host cell genomes of both dividing and nondividing cells, providing long-term stable expression of the gene of interest. Improvements of the vector packaging platform or the manufacturing protocol can provide a global solution to the production of many different LVs. Recent research has shown that many cellular restriction factors (RFs) inhibit specific steps of the lentiviral life cycle.[7,8,9] Some RFs are inducible by sensing viral components and activating the interferon (IFN) signaling cascade, while other RFs are ubiquitously expressed for direct antiviral functions. Ferreira et al reported that LV production titer is not limited by induced intracellular innate immunity in HEK293T cells, because there was no detectable IFN cytokine release during the packaging process.[10] This is likely due to the large T-antigen (TAg) and adenovirus E1A, which are expressed in HEK293T and inactivate the tumor suppressors p53, IRF3, and other IFN-dependent transcription downstream of RNA and DNA sensing.[11,12,13,14]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.